{"name":"Sutro Biopharma, Inc.","slug":"sutro","ticker":"STRO","exchange":"NASDAQ","domain":"sutrobio.com","description":"Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung","hq":"South San Francisco, CA","founded":0,"employees":"137","ceo":"Bill Newell","sector":"Biotech — Oncology / ADC","stockPrice":39.78,"stockChange":0.18,"stockChangePercent":0.45,"marketCap":"$659M","metrics":{"revenue":102484000,"revenueGrowth":-21.4,"grossMargin":-62.4,"rdSpend":166417000,"netIncome":-191086000,"cash":141428000,"dividendYield":0,"peRatio":-7.9,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"STRO-001 patent cliff ($0.0B at risk)","drug":"STRO-001","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"STRO-002 patent cliff ($0.0B at risk)","drug":"STRO-002","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Sutro Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Sutro Biopharma reported its fourth quarter and full year 2023 financial results, highlighting a strong revenue growth and a significant increase in its cash position.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Sutro Biopharma Announces Collaboration with Merck to Develop Novel ADC Therapies","summary":"Sutro Biopharma announced a collaboration with Merck to develop novel ADC therapies, expanding its pipeline and strengthening its position in the ADC space.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Sutro Biopharma Announces Positive Interim Data from Phase 1 Clinical Trial of STRO-001","summary":"Sutro Biopharma announced positive interim data from a Phase 1 clinical trial of STRO-001, its lead ADC candidate, demonstrating promising efficacy and safety profiles.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE43eFZTejdvWTg4dXpocTdCbWN5LWtWMlcweGpMdTF0N1BGQzZIS2hDQ1R2aVZmTGdScFkzTGhNSnhyOHVFdUozU194MWRLTy1VZXNQSnl6a1dRX2dyMFBNbDdTRUhKZWVBTzhJMzJiQW8td0x2Wk5nTGlZWGRqMWM?oc=5","date":"2026-01-22","type":"pipeline","source":"Yahoo Finance","summary":"Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock? - Yahoo Finance","headline":"Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxORVZBaGtfS2FKbm5oWnZWVUU0T1dLQk94N2VoTjFjeGk1azUzY2UwZEREc0NsZUJGM19Va3hIaVdxUXdoLWpVcFp6OWpUWmxOMnAyT2daRDZuVExXSFkzM3lxckJEQ3ZqV0RYd1BZemFCODFLRU11MU40bS0xVHBuSnYxNHpwcFJac2lfMkJYOXBmeVdZOFB0ZnNyRmUza2FHYzFjNXNteXNxTGRYVlQtbnc1M2M4TEJKWmx5Q1I5RVJYQjlxMGJwTGZUMjQyRG93T25EVjktY25nSm56STJBaGVPdkR1UdIB6wFBVV95cUxNaHNfdkFpbFNiclQ1U1pRZGllUl95SkVxV19tU3BaRlhoQ05DTXdiXzItYXkweVA5NlJFZGoxdldMaDhUb0xCaURqaHA5WHgxVkd0dkMyQ0lKQ3A2bHUwcko3dHJXbVVzYzRFX0JCLUUweDBTbUdxMFhYdDh4XzMwWURWQ09tS0o0RVE5Y01lQk43NG1YUlMwSnd5alhoQTRWVUhGM19wNEcxcXlJSzE1cUFSd3g0RlpLdTZTbWJ6SmNLTFJqZm1TR3BZSk45eFV4QTdQM1ZtRGEzOFJhOTZ3OFRueTF2ajkyamkw?oc=5","date":"2025-12-31","type":"pipeline","source":"simplywall.st","summary":"Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46% - simplywall.st","headline":"Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQTm9qRFRSdjNtTWdKS0gwMkIwT2R4eGF3OFBnN0tDMHg4MFBYc0tYV0hOYUluUVhieWRLdTktNTNYZjRaQVJ6eEtBV3hYeERtMnV0ZUZZelNDdHZxQk83b08takttQjlDREVFWnVFODJlWTVPU2lCMzFjS1Yxc2FwZTJCZzVVWVFZLXV4NXRJMjNvY2RSMmhvQXdFM0tCVFVEQVRtV1AzT0NlT0pVWktiZkUyV2VaVWFzcE1ZcXlTd1d4QkZEZWFBazgzM1JIVWEwaWlmQ3JqREloZ0puYm5HVUR4SkQ3RTZkTUdSLWJCeWJJd0YzenpUcVZGNGc5c0QtdWhqaDQ2clFrakU?oc=5","date":"2025-12-19","type":"pipeline","source":"Finansavisen","summary":"Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines - Finansavisen","headline":"Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQVE82Q2l1VTVucnNWSGg3VzJCdVNVUnhtanF5VDRYMGFHdUJfSmM0ZlhEcC1zZENjNmJJMWdBNWp0U3pqbnJvYlZaOGlEaGMtcjhNdWZKOGVBbWFrdVFZVXNSOEQ1ajZZVVM1cGFhNWFFdDFFcXZKU1FLMDhodHlocE5lbEZIZ05jajRBOWpsNDg?oc=5","date":"2025-08-08","type":"deal","source":"Fierce Biotech","summary":"Ipsen hands back Sutro's ROR1 ADC at center of $875M deal - Fierce Biotech","headline":"Ipsen hands back Sutro's ROR1 ADC at center of $875M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOa25WUnpMMW45UklsakVYSkN4Yi1UV2ZfSkpGd2syeE1WeUlzcXZLbnZwNi1sTzlOcmQ3bkR0dUJ1WWlpZUhlbzVKS1ZXTHBSQkY0dW1vSjhZSW1RY0gtRmNlWVkyU2JrSGxJdF9oYUIxZGtGWE9PaDIxd3JkZV9ob3Z4R3hFNjcx?oc=5","date":"2025-03-14","type":"pipeline","source":"pharmaphorum","summary":"Sutro puts lead ADC on hold, cuts staff and changes CEO - pharmaphorum","headline":"Sutro puts lead ADC on hold, cuts staff and changes CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1qQkNhTnY0dmFfSFp2NWd3cWRQWDFQVDdtMU8za3V4UTBTS0RNdUJuUXdRTzV4QmJZWGlRYW5HWnp1aFJYWUVJYWdFNGVkNHVaTW5z?oc=5","date":"2025-03-13","type":"pipeline","source":"firstwordpharma.com","summary":"Half of Sutro's staff — and its CEO — are slated for departure amid ADC reshuffle - firstwordpharma.com","headline":"Half of Sutro's staff — and its CEO — are slated for departure amid ADC reshuffle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNTEZhZzl1dU1seHhMb1F3VzFXSXBYWjR3RWdtWFRlcmJzbXVnbjBsVjVnUU13c0FfdlhOb2RvQXJsN3hrMm9rY1U3OWEyUHlnWkY1SlVlN1BfQ1FsTVpMX2wzNTdxT2ZpdWk3b3AxeTVxRzlLc2o5MGNXZ2VMVWRXaWlSZ25GcXJJY3hSYzk3Y1JObk56VHNjTEgzcVBURE9RelFMU2lpOUR5azBiLV9nT05YV1A2QQ?oc=5","date":"2025-03-13","type":"pipeline","source":"Stock Titan","summary":"Sutro Biopharma Unveils Major Strategic Shift with $317M War Chest Through 2026 - Stock Titan","headline":"Sutro Biopharma Unveils Major Strategic Shift with $317M War Chest Through 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNZVNtaE0yWU5IRWZydDkzbmVGNWtMV0s3SkFuS2VpWFI1UXRrZmxhVURLRlRTYWJXYjkzQW4yYXNxS01WdTMwSGlyR0VpQk4yNU1hRF9vUW91alJnTzVjcmRCczZVOEw0aHdxTXplcnFQT0NqQjRmRE01RndBVXFpV1RWWVJDWnYzZll6YTdEdnJjR3NaUFZ5VzZXOWdWX05JVGc?oc=5","date":"2025-01-02","type":"deal","source":"Seeking Alpha","summary":"Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless (NASDAQ:STRO) - Seeking Alpha","headline":"Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless (NASDAQ:STRO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOMU9SLVRYUWFlT0RpNFNnRjVYWTAyNzVDaEZKekhzY1lsMkkySlJEUzBublNVanBfdWNoSXlJNFYzTUpGSTYwZFJrUF9DX0JWUHhDalc4Q0JEODlKekU3VWRCaGE1UFJ3UDBXUmFDWHNFX1V3dmJzazFhRVRUaEE1QTZtXzNFYWhGR2lkRVJKVGJrRVJGMHhma2dkcDZnbks3clZRNncyR1JZcXdFT3c?oc=5","date":"2024-04-02","type":"deal","source":"BioSpace","summary":"Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC - BioSpace","headline":"Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxON1NlVGZFVzJ6QWdtdmNXaDVHb04xcWdPMFp5Tm1ROEttcURqTk5jaFhOVWY5aks2Zm91bEtRMGNOYlh6enJ5MjFxdW5uUkVjbW5GWTlWNnI2VXp0bHVvMmQ4UEsxVlktRk1LT3ZuOW9EbERia01kZFN4cVAyalZ4ZXNTTmJ2WnJnbFRoVDlZZkNscjU3VVZyU2c0M2NlUEVU?oc=5","date":"2024-04-02","type":"pipeline","source":"bioworld.com","summary":"Ipsen enters ADC space licensing Sutro’s ROR1 drug STRO-003 - bioworld.com","headline":"Ipsen enters ADC space licensing Sutro’s ROR1 drug STRO-003","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNcE5hQVBfb0NYTXlCY3VBM1hTY0xvVUJYMmQtSW5ZSHpxWTlZZWdyNm9CTmJQUkNqeWNCSUFYbTd1eVlLZk9OYm45TTFrQ3JoNEc4NUljVnc4S2xqcjJPaGhPazdPcEEzaHpkNjJCSzBpdUJhQmJGQWxFR1pOc0VlbGlHN3JCa3FiVUxtTU02NDBBcW9aY2doQVhsN0QyMW16VURPb2xMbw?oc=5","date":"2024-04-02","type":"pipeline","source":"PMLiVE","summary":"Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate - PMLiVE","headline":"Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxOSjJJekNFWFNQbXR1NWRQZENvX1hmV1hJT0NGUFdoZnQ2R3ZMMXJPeWR0SFQ5YUg3V2FTeGxyTEVoQXNmRHd6QThpY245cGNSRUFkRUFqc25VNWR2MTZwTjhteUp5eWNQdUtXbm9VNzBkdFI1ZVRJRi1HX1dhMVgxcHNfdEtPQ0lONzhlaWQxYVFJN0NoZ0NnNVJ5WEYybkhiNDJTZmxlWXZUZHhWS195V2FWNG9rZHVJZi1EMWo2UmxsemlxRGlSRTdrejJXRzNIRnBLMjBDZUlPUERCYjgyQjNmb1JpYkJUejlOQjRqcEJJbXp4enRhMzdIZFFCeGMyZkZHZmhKYjl5OXJqYWlzM2hWWEE2UU1JRmZFQnJB?oc=5","date":"2022-06-27","type":"deal","source":"PR Newswire","summary":"Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs) - PR Newswire","headline":"Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug","sentiment":"neutral"}],"patents":[{"drugName":"STRO-001","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0},{"drugName":"STRO-002","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer AG","Seattle Genetics","Genmab A/S"],"therapeuticFocus":["Oncology","Antibody-Drug Conjugates (ADCs)"],"financials":{"source":"sec_edgar+yahoo","revenue":11305000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":11305000,"period":"2019-12-31"},{"value":12277000,"period":"2019-09-30"},{"value":10525000,"period":"2019-06-30"},{"value":8629000,"period":"2019-03-31"},{"value":38419000,"period":"2018-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":166417000,"rdSpendHistory":[{"period":"2025-12-31","value":166417000},{"period":"2024-12-31","value":252043000},{"period":"2023-12-31","value":180425000},{"period":"2022-12-31","value":137171000}],"sgaSpend":41019000,"operatingIncome":-104952000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-104952000},{"period":"2024-12-31","value":-238453000},{"period":"2023-12-31","value":-89278000},{"period":"2022-12-31","value":-128943000}],"netIncome":-191086000,"netIncomeHistory":[{"period":"2025-12-31","value":-191086000},{"period":"2024-12-31","value":-227461000},{"period":"2023-12-31","value":-106793000},{"period":"2022-12-31","value":-119204000}],"eps":-22.49,"epsHistory":[{"period":"2025-12-31","value":-22.49},{"period":"2024-12-31","value":-29.4},{"period":"2023-12-31","value":-17.8},{"period":"2022-12-31","value":-23.5}],"cash":58130000,"cashHistory":[{"period":"2025-12-31","value":58130000},{"period":"2024-12-31","value":190304000},{"period":"2023-12-31","value":69268000},{"period":"2022-12-31","value":47254000}],"totalAssets":173830000,"totalLiabilities":306282000,"totalDebt":15674000,"equity":-132452000,"operatingCashflow":-177231000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-177231000},{"period":"2024-12-31","value":-191540000},{"period":"2023-12-31","value":-111616000},{"period":"2022-12-31","value":3549000}],"capex":-1695000,"capexHistory":[{"period":"2025-12-31","value":-1695000},{"period":"2024-12-31","value":-3098000},{"period":"2023-12-31","value":-4315000},{"period":"2022-12-31","value":-7858000}],"freeCashflow":-178926000,"dividendsPaid":null,"buybacks":0,"employees":137,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":8662000,"ebit":-36515000,"ebitda":-34891000,"period":"2025-12-31","revenue":11647000,"epsBasic":null,"netIncome":-46762000,"rdExpense":36642000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-33657000},{"sga":8741000,"ebit":-46450000,"ebitda":-44550000,"period":"2025-09-30","revenue":9693000,"epsBasic":-6.7,"netIncome":-56857000,"rdExpense":39853000,"epsDiluted":-6.7,"grossProfit":null,"operatingIncome":-38901000},{"sga":10343000,"ebit":-826000,"ebitda":1074000,"period":"2025-06-30","revenue":63745000,"epsBasic":-1.4,"netIncome":-11499000,"rdExpense":38325000,"epsDiluted":-1.4,"grossProfit":null,"operatingIncome":15077000},{"sga":13273000,"ebit":-65325000,"ebitda":-63425000,"period":"2025-03-31","revenue":17399000,"epsBasic":-9.1,"netIncome":-75968000,"rdExpense":51597000,"epsDiluted":-9.1,"grossProfit":null,"operatingIncome":-47471000},{"sga":9030000,"ebit":-61398000,"ebitda":-59530000,"period":"2024-12-31","revenue":14809000,"epsBasic":null,"netIncome":-72443000,"rdExpense":71037000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-65258000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-5.9,"netIncome":null,"rdExpense":null,"epsDiluted":-5.9,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":39.78,"previousClose":39.6,"fiftyTwoWeekHigh":41.88,"fiftyTwoWeekLow":6.7,"fiftyTwoWeekRange":"6.7 - 41.88","fiftyDayAverage":29.08,"twoHundredDayAverage":15.45,"beta":1.64,"enterpriseValue":530308640,"forwardPE":-7.9,"priceToBook":-2.58,"priceToSales":6.43,"enterpriseToRevenue":5.17,"enterpriseToEbitda":-5.43,"pegRatio":0,"ebitda":-97628000,"ebitdaMargin":-95.3,"freeCashflow":-112393376,"operatingCashflow":-177231008,"totalDebt":15674000,"debtToEquity":0,"currentRatio":2.01,"returnOnAssets":-23.4,"returnOnEquity":0,"analystRating":"1.5 - Buy","recommendationKey":"buy","numberOfAnalysts":11,"targetMeanPrice":35.73,"targetHighPrice":55,"targetLowPrice":9,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.3,"institutionHeldPercent":51.2,"sharesOutstanding":16567887,"floatShares":13306806,"sharesShort":977108,"shortRatio":4,"shortPercentOfFloat":5.9,"epsTrailing":-22.49,"epsForward":-5.04,"revenuePerShare":12.06,"bookValue":-15.43,"officers":[{"age":54,"name":"Ms. Jane  Chung R.Ph.","title":"CEO & Director"},{"age":52,"name":"Mr. Gregory K. Chow BA, CPA, MBA","title":"Chief Financial Officer"},{"age":61,"name":"Dr. Hans-Peter  Gerber Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Dr. James R. Swartz DSc, Ph.D., Sc.D.","title":"Founder"},{"age":null,"name":"Mr. Devendra  Luhar","title":"Senior Vice President of Technical Operations"},{"age":51,"name":"Mr. David  Pauling J.D., M.A.","title":"Chief Administrative Officer & General Counsel"},{"age":null,"name":"Ms. Kari E. Leetch","title":"Senior VP and Head of People & Culture"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.sutrobio.com","phone":"650 881 6500"}}